Share Name Share Symbol Market Type Share ISIN Share Description
Seneca Growth Capital Vct Plc LSE:HYG London Ordinary Share GB0031256109 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 22.00p 20.00p 24.00p 22.00p 22.00p 22.00p 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -0.1 -0.7 - 2

Seneca Growth Capital Vct Share Discussion Threads

Showing 701 to 724 of 725 messages
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
DateSubjectAuthorDiscuss
19/9/2019
16:26
Good to see both Arecor and ImmBio progressing according to the Oxford Tech VCT results out this morning: Https://www.investegate.co.uk/oxford-tech-2-vct--oxh-/gnw/oxford-technology-2-venture-capital-trust-plc---half-year-report/20190919070000H3436/ "Arecor and ImmBio are both about 20% of the portfolio. Arecor have started dosing in their Phase 1 clinical trial of rapid action insulin. They have also signed multiple development agreements to develop room temperature liquid formulations with global pharma companies. In March, OT2 invested £8,230 in ImmBio. This investment enables ImmBio to go through the process of technology transfer of PnuBioVax vaccine strains to the Chinese National Biotech Company as required by the license agreement. Discussions are also ongoing with pharma companies in other regions of the world."
rivaldo
10/7/2019
14:09
A report on the Oxford Tech VCT's AGMs last month includes this section on Arecor and Immbio (thx to Tim Grattan): Https://sharesoc.ning.com/forum/topics/the-agm-forum?id=6389471%3ATopic%3A613&page=62#comments "Arecor (OT2, OT3 and OT4) http://arecor.com/ Sarah Howell (CEO) gave the presentation for Arecor, see link below for slide deck: https://www.oxfordtechnologyvct.com/admin/jscripts/tiny_mce/plugins... Sarah also gave a presentation at the 2017 Oxford VCT AGMs (link to 2017 notes https://sharesoc.ning.com/forum/topics/the-agm-forum?commentId=6389... ), so it was interesting to learn about the progress in the last two years. Since the 2017 the company has managed to secure funding from three new VCT/EIS institutional investors (Albion, Downing and Calculus) and they have continued with their two main business activities: 1) Formulation work for big pharma charged as fee for service (plus milestone payments/royalties if work leads to product launch) 2) In house development of improved products to treat type I diabetics. There has been a switch in emphasis in the last two years from developing stable liquid glucagon solutions suitable for parenteral administration, to developing improved stable insulin formulations for parenteral administration, the reasons for this are entirely commercial. Arecor now have main two products in development, the first is a faster acting formulation, which avoids the time lag for onset of action which is seen with conventional formulations. The second development product is 10X more concentrated than conventional formulations (but still acts reasonably rapidly), making it suitable for administration via an insulin pump and especially suitable for children who use insulin pumps. The commercial potential for such products is estimated to be substantial, for example, Eli Lilly have successfully developed one product (Humulin) which is 5X more concentrated than standard and this commands annual sales of $1.2Bn. One direct competitor (Adocia) recently signed a deal with Lilly worth over $500m in upfront payments and milestones plus royalties, the deal eventually fell through but not before they had collected substantial milestone payments, furthermore, they have now re-licenced their product to a Chinese company in a regional deal (China only) worth $130m in milestones plus double digit royalties. Another competitor (Thermalin) recently signed a deal with Sanofi worth over $700m in milestones plus double digit royalties. I spoke to Sarah after the meeting to ask about the status of the glucagon product, I was told that it is still going, but it is now assigned a lower priority and it is currently being funded by grants. I also asked about the technical difficulties encountered when producing the more concentrated formula for insulin. Apparently the main problem is not a solubility or viscosity issue, but one of bioavailability at the site of action and this is related to the degree of binding of the zinc at the centre of the insulin hexamer. Immbio (OT2, OT3, OT4) http://www.immbio.com/ Andrea Mica gave the presentation on behalf of the company, see link to presentation slide deck below https://www.oxfordtechnologyvct.com/admin/jscripts/tiny_mce/plugins... ImmBio previously presented at the 2017 Oxford VCT AGMs (link to 2017 notes https://sharesoc.ning.com/forum/topics/the-agm-forum?commentId=6389... ) so this was a timely update. Earlier this year Immbio signed a multi-million licensing deal with the largest Chinese Vaccine Pharma company, CNBGSinopharm, for co-development and commercialization in China of ImmBio’s lead product PnuBioVax which is a vaccine to treat pneumococcal infections, a major cause of mortality in the young and elderly (1.6M deaths worldwide per annum), Current pneumococcal vaccines are relatively expensive and they are becoming less effective as different strains emerge, this problem is being exacerbated as antibiotic resistance becomes more prevalent (25% cases of all pneumonia now show antibiotic resistance). Immbio’s vaccines (including PnuBioVax) have a novel mechanism of action: they protect against pathogens by mimicking the natural immune response to infection by utilising heat shock proteins. These vaccines should be active against all stains of the targeted pathogen (not just some) and they should be relatively cheap to produce. The lead product PnuBioVax has completed Phase I studies and preparations are underway for a Phase II study in elderly patients. Immbio are intending to raise £4.5m to fund the Phase II study, although this figure would be reduced if they sign further regional licencing deals for PnuBioVax."
rivaldo
29/4/2019
14:47
Results are out today (not shown above for some reason), with a 65.1p per share NAV. More importantly, following the 10p dividend paid in January, HYG plan to declare another 18p dividend next month: Https://www.investegate.co.uk/seneca-growth-cap---hyg-/rns/final-results/201904290852223247X/ NAV progress will be dependent as usual on SCLP and ODX in the listed arena, whilst OR Productivity seems to be progressing OK in the unlisteds on a £0.7m valuation.
rivaldo
09/1/2019
16:23
Sorry I should have been clearer. The discount is disappearing so once 10p is paid, this will trade at a premium to NAV won't it? If so, I can't see that justified by SCLP or other performance. That said, I am very long here if continually disappointed by Scancell
jonesy100
09/1/2019
12:47
Of course the price will either multi-bag if SCLP does well or will fall if not. But I'm also confident that ODX will do well over time. And there's also a large investment in OR Productivity, plus Arecor seems to be doing pretty well. Plus HYG now have a large cash pile to support the share price and to invest in new ventures or support existing investments.
rivaldo
09/1/2019
11:31
Thanks. For some reason was not showing up on my feed service. I am surprised people are chasing this for the divi. If Nav low 60s including Hallmarq, the price will adjust fast unless Scancell delivers. Or am I wrong?
jonesy100
08/1/2019
23:05
Try here Jonesy100: Https://www.investegate.co.uk/seneca-growth-cap---hyg-/rns/dividend-declaration/201812280700026071L/
rivaldo
08/1/2019
21:42
Hi Rivaldo, where is the info posted on the 10p special dividend? Thanks
jonesy100
08/1/2019
15:11
For the record, HYG are paying a 10p special dividend - the ex-div date is Thursday, so evidently a few people are keen to get in before then! I've done a quick update of the thread header post for the record.
rivaldo
18/12/2018
11:32
Big news - Hallmarq has been sold, so HYG will receive just over £2.9m cash (against the current £3.65m m/cap): Https://www.investegate.co.uk/seneca-growth-cap---hyg-/rns/update-on-hallmarq/201812180956318171K/ Current NAV is 63.4p per share, including SCLP, ODX and the unquoteds. Since most of this is now cash there will soon be distributions to shareholders. I had hoped that Hallmarq would simply grow and grow for a few more years. Not to be. The hope now is that SCLP and ODX in particular will realise their potential. I hold ODX separately and am pretty optimistic about it. SCLP I know much less about and looks to be a toss of the coin bet really.
rivaldo
13/9/2018
08:58
Good news from Arecor (current carrying value £252k): Https://www.biospace.com/article/biopharma-company-arecor-raises-6m-for-revolutionary-diabetes-treatments/ "Biopharma Company Arecor raises £6m for revolutionary diabetes treatments Published: Sep 12, 2018 10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the application of its technology platform, Arecor is creating faster working, more effective drugs that help progress the creation of the next generation of artificial pancreas systems. The Company’s ultra-rapid acting insulin and ultra-concentrated insulins more closely mimic the insulin profile and response to glucose of healthy individuals, improving health outcomes and quality of life for people living with diabetes while reducing the wider costs to health services and society. Arecor has developed a series of differentiated and proprietary formulations of generic insulin and glucagon drugs, which are used in the regulation of blood glucose. In people with diabetes, insulin is either lacking, not enough is produced or when produced, the insulin cannot be used effectively. Arecor plans to complete a series of first-in-man clinical trials for each of its three diabetic compounds and ultimately to partner with specialist diabetes companies for late stage clinical studies and global market access. The company’s insulin and glucagon products, which are set to transform diabetes treatments, could have peak annual sales of between $200 million and $1 billion each. etc"
rivaldo
10/8/2018
16:09
The managers of the Oxford Technology VCT portfolios gave a presentation at their AGM in late July - it was covered by Sharesoc, who posted these rather positive comments from management on ImmBio and Arecor: "ImmBio (OT2, OT3 and OT4) hxxp://www.immbio.com/ The level of interest in ImmBio’s lead pneumococcal vaccine (ImmBioVax) shown in the recent past by western based Pharma companies has been disappointing, but there has been considerable interest from China’s CNBG (head of terms agreement recently signed) which appears to be beginning to stimulate interest from Western Pharmas. Arecor (OT2, OT3 and OT4) hxxp://arecor.com/ The company’s unique technology of protein solubilisation and stabilisation is currently being developed to produce improved formulations for the management of diabetes, Arecor have recently attracted grant funding of just over £1m to assist with this development."
rivaldo
25/7/2018
11:49
Nearly 30% discount to NAV - either cautious or not very hopeful?
toffeeman
25/7/2018
11:04
Interims are out: Https://www.investegate.co.uk/hygea-vct-plc--hyg-/gnw/hygea-vct-plc---half-year-report/20180724070029H6722/ NAV of just over 62p per share. No commentary on the unquoteds, though good to see no writedowns and OR Productivity holding its value. Most importantly, there's this: "I have previously expressed some optimism regarding potential liquidity events in the portfolio and your Board remains of the view that such an event may occur before the Company's year-end." I'm not holding my breath given the track record to date! However, I am very hopeful that Hallmarq will produce a substantial return - at some point - and that this is the likely company set for the "liquidity event". If SCLP ever actually takes off we'll be many quids in - if HYG haven't had to sell most of the holding by then.
rivaldo
19/6/2018
10:50
hxxp://arecor.com/2018/ £1m grant for Arecor - every little helps!!! Best regards SBP
stupidboypike
03/5/2018
10:09
Hi Toffeeman, good to see you here. It's been a long wait....like SCE :o)) Apologies for the delayed reply, but I don't visit here too often as it's only a small holding, which I may add to if I become aware of portfolio news before the wider market by monitoring investee news flow.... I can't really say more than to point you in the direction of this RNS from HYG which should explain it all. Https://www.investegate.co.uk/hygea-vct-plc--hyg-/gnw/hygea-vct-plc---circular-posted-and-notice-of-g---/20171215144748H6567/ Good to see from Oxford Tech VCT's results this morning that both Arecor and ImmBio seem to be making progress: "At the end of November 2017, we made a £200k follow-on investment into Arecor, making it the second largest holding in the Company's portfolio. Arecor is a potentially world class pharmaceutical research company based in Cambridge and has a very advanced diabetes drug formulation technology. During the past year Arecor has announced significant progress, including a licence agreement with a major global healthcare company, as well as the successful pre-clinical development of stable rapid-acting, ultra-concentrated insulin for the significantly enhanced treatment of type 1 diabetes. It has had other good news flow and won an Innovate grant. The company is still trying to finalise the investment terms for the full £6m round it is seeking, and there is a risk that the terms may be at a lower price than that at which we invested in November; we have therefore taken a prudent view with our valuation and hence there is a small reduction in the value of our investment in the year. The recent investment of £30k in ImmBio was in a new class of share with a significant preference. This has resulted in an uplift in its valuation of £83k. The investment was made to support continued commercialisation of its PnuBioVax Vaccine. The final results to come from their First-in-Human study were positive and was found to be safe and well tolerated, and capable of producing antibody responses against key S. pneumoniae antigens broadly conserved across strains. Negotiations are progressing with first licensees for the vaccine, and a further £12,000 was committed in April 2018 to allow time for these conversations to progress."
rivaldo
19/4/2018
17:00
Hi Riv - keep 'bumping into you!' Can you tell me about the Senneca link? I have a Senneca EIS and they say they are launching a VCT and mention HYG. I can't see what the advantage is of doing a Senneca VCT when one can by this stock directly. Any advice appreciated.
toffeeman
07/2/2018
11:01
2017 results are out: Https://www.investegate.co.uk/hygea-vct-plc--hyg-/gnw/hygea-vct-plc---final-results/20180206082101H6370/ NAV is steady at around 64p. However, this sentence is rather intriguing: "Current indications are that the unquoted portfolio may see a liquidity event sooner than previously envisaged" I wonder if this refers to Hallmarq? I notice there's no specific reference to Hallmarq in the narrative - perhaps HYG don't want to say too much as they know there's something happening? With annual running costs now seemingly reverting to Seneca and the B shares, perhaps things are looking interesting now.
rivaldo
08/11/2017
10:39
Although a relatively small holding, Arecor carries on advancing too:- hxxp://www.arecor.com/news-events/ particularly "Arecor Announces License Agreement with Global Pharmaceutical Company" Best regards SBP
stupidboypike
08/11/2017
10:10
Quarterly update just out - NAV barely changed at 64p per share: Https://www.investegate.co.uk/hygea-vct-plc--hyg-/gnw/hygea-vct-plc---update-for-the-quarter-ended-30---/20171108070032H7889/ Glide is gone, SCLP bobbing about. ODX is now the only other listed holding (which I hope they hold on to as it's imo on the cusp of a great leap forwards....). Interestingly: "In the absence of realisations, the Board continues to investigate ways to mitigate the ongoing running costs of the Company and has had discussions with various parties with a view to the expansion of the capital and investment base. Once any such discussions are sufficiently advanced, an announcement will be made but at present there is no certainty that any of the discussions will lead to a proposal.£ This is one of my smallest investments (and longest-held!). I'll continue holding as the upside from Hallmarq, ODX and/or SCLP could be significant. I believe Hallmarq justifies much of the current NAV by itself, so hopefully the downside is limited. But it's frustrating for sure....
rivaldo
13/4/2017
09:37
This is not insignificant:- hxxp://www.cambridge-news.co.uk/business/life-sciences/arecors-45m-deal-rubber-stamped-12875547 Hygea's current valuation implies a valuation on Arecor (the whole company) of around £6.8M. Best regards SBP
stupidboypike
15/9/2016
10:36
Good article about Arecor - "experiencing significant growth": Http://www.cambridge-news.co.uk/arecor-moves-from-one-park-to-another/story-29712050-detail/story.html Extract: "Dr Sarah Howell, CEO, Arecor commented on the move: "We're experiencing significant growth and we required enhanced facilities that could meet our expansion needs, both today and well into the future." As Arecor's diabetes product moves into clinical trials and the organisation's partnerships with major pharma and biotech companies continue to expand, it expects to experience significant growth."
rivaldo
01/9/2016
12:40
Interims out - NAV down to 69.1p due to the decline in SCLP's share price. SCLP is up some 10% since 30/6, so I would expect NAV to be up nearer say 71p now: Http://www.investegate.co.uk/hygea-vct-plc--hyg-/gnw/hygea-vct-plc---half-yearly-report/20160831070031H8373/ Hallmarq is still progressing very well. It's surely just a matter of time before it IPO's on AIM, at which point I'd expect NAV serious upside. I'm also hopeful for the £450k carrying value in AIM-quoted ODX - this could be worth a lot more in a few months' time with decent news flow.
rivaldo
26/7/2016
07:15
More good news from Arecor:- hxxp://www.arecor.com/news-events/jdrf-announces-partnership-arecor-ltd/
stupidboypike
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
Your Recent History
LSE
HYG
Seneca Gro..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191014 20:39:07